CNS drug development is complex, and partnering with an integrated CRO/CDMO can reduce your timelines by up to 40%. Learn more in The Altascientist.

In this issue of The Altascientist, we detail the complexities of central nervous system (CNS) drug development programmes. In addition, we share how partnering with an integrated CRO/CDMO can reduce your timelines by up to 40% as your compound advances through each study phase. Topics covered include:

  • Preclinical safety and toxicity testing
  • Formulation and manufacturing for nonclinical and clinical studies
  • Maximising early phase clinical trials
  • Bioanalytical considerations.

Download Now

Asset 2: Reduce CNS Drug Development Timelines by Up to 40%

PDF, Size 0 kb

Topics